The inhibitory influence of adiponectin on the growth of the murine endothelial cell line HECa 10 in vitro

Endokrynologia Polska

Volumn 60, Issue 3, 2009, Pages 166-171

  Połowinczak Przybyłek, Joanna ^a   Mełeń Mucha, Gabriela ^b  

^a Regional Oncological Centre   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adiponectin; Endothelial growth; In vitro

Indexed keywords

ADIPONECTIN; THALIDOMIDE;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CULTURE; CELL GROWTH; CELL IMMORTALIZATION; CELL STRAIN; CELL STRAIN HECA 10; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG POTENCY; ENDOTHELIUM CELL; GROWTH INHIBITION; IN VITRO STUDY; LYMPH NODE; MOUSE; NONHUMAN;

ADIPONECTIN; ANIMALS; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; THALIDOMIDE;

EID: 67749094962     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Scherer PE, Williams S, Fogliano M et al. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995; 270: 26746-26749.
2. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 1996; 271: 10697-10703. (Pubitemid 26145805)
3. Maeda K, Okubo K, Shimomura I et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 1996; 221: 286-289. (Pubitemid 26136463)
4. Nakano Y, Tobe T, Choi-Miura NH et al. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996; 120: 803-812. (Pubitemid 26385421)
5. Pineiro R, Iglesias MJ, Gallego R et al. Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett 2005; 579: 5163-5169. (Pubitemid 41318086)
6. Pajvani UB, Du X, Combs TP et al. Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 2003; 278: 9073-9085. (Pubitemid 36800387)
7. Waki H, Yamauchi T, Kamon J et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-40363. (Pubitemid 37248604)
8. Fruebi J, Tsao TS, Javorschi S et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001; 98: 2005-2010. (Pubitemid 32165613)
9. Yamauchi T, Kamon J, Ito Y et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-769. (Pubitemid 36735700)
10. Arita Y, Kihara S, Ouchi N et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79-83. (Pubitemid 29299050)
11. Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia. J Clin Endocrinol Metab 2002; 87: 2764-2769. (Pubitemid 34655342)
12. Yamamoto Y, Hirose H, Saito I et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci (Lond) 2002; 103: 137-142. (Pubitemid 34886305)
13. Kumada M, Kihara S, Sumitsuji S et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003; 23: 85-89. (Pubitemid 36091630)
14. Ouchi N, Ohishi M, Kihara S et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 2003; 42: 231-234.
15. Trujillo ME, Scherer PE. Adiponectin: journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med 2005; 257: 167-175.
16. Nishizawa H, Shimomura I, Kishida K et al. Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 2002; 51: 2734-2741. (Pubitemid 34970926)
17. Xu A, Chan KW, Hoo RL et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005; 280: 18073-18080. (Pubitemid 41389052)
18. Yamauchi T, Kamon J, Minokoshi Y et al. Adiponectin stimulates glucose utilization and fatty acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-1295. (Pubitemid 35373562)
19. Ouchi N, Kihara S, Arita Y et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-B signaling through a cAMP-dependent pathway. Circulation 2000; 102: 1296-1301. (Pubitemid 30728130)
20. Yokota T, Oritani K, Takahashi I et al. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 2000; 96: 1723-1732. (Pubitemid 30661055)
21. Yamauchi T, Kamon J, Waki H et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003; 278: 2461-2468. (Pubitemid 36801322)
22. Ouchi N, Kihara S, Arita Y et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476. (Pubitemid 30005109)
23. Baranowska B, Bik W, Baranowska-Bik A et al. Neuroendocrine control of metabolic homeostasis in Polish centenarians. J Physiol Pharmacol 2006; 57: 55-61. (Pubitemid 46548801)
24. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004; 89: 2563-2568. (Pubitemid 38766332)
25. Ouchi N, Kobayashi H, Kihara S et al. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. J Biol Chem 2004; 279: 1304-1309. (Pubitemid 38082655)
26. Kobayashi H, Ouchi N, Kihara S et al. Selective suppression of endothelial cell apoptosis by the high molecular weight form of adiponectin. Circ Res 2004; 94:e27-31.
27. Bråkenhielm E, Veitonmäki N, Cao R et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004; 101: 2476-2481. (Pubitemid 38269336)
28. Shibata R, Ouchi N, Kihara S et al. Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of AMP-activated protein kinase signaling. J Biol Chem 2004; 279: 28670-28674. (Pubitemid 38900150)
29. Kimura T, Takagi H, Suzuma K et al. Adiponectin stimulates angiogenesis in developing murine retina Invest Ophthalmol Vis Sci 2005; 46: E-Abstract 3897.
30. Mahadev K, Wu X, Donnelly S et al. Adiponectin inhibits vascular endothelial growth factor-induced migration of human coronary artery endothelial cells. Cardiovasc Res 2008; 78: 376-384. (Pubitemid 351556105)
31. Tytarenko RG, Lyzogubov VV, Kaliappan S et al. Adiponectin peptide inhibits proliferation of endothelial cells and inhibits vessel growth in mouse model of laser induced CNV. Invest Ophthalmol Vis Sci 2008; 49: E-Abstract 3431.
32. von Moos R, Stolz R, Cerny T et al. Thalidomide: from tragedy to promise. Swiss Med Wkly 2003; 133: 77-87.
33. Sampaio EP, Sarno EN, Galilly R et al. Thalidomide selectively inhibits tumor necrosis factor-α production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
34. Rowland TL, McHugh SM, Deighton J et al. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology 1998; 40: 11-20. (Pubitemid 28434949)
35. Moller DR, Wysocka M, Greenlee BM et al. Inhibition of IL-12 production by thalidomide. J Immunol 1997; 64: 971-978. (Pubitemid 127471057)
36. Shannon EJ, Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concavalin A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology 1995; 31: 109-116.
37. Mc Hugh SM, Rifkin IR, Deighton J et al. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol 1995; 99: 160-167.
38. D'Amato RJ, Loughnan MS, Flynn E et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Scie 1994; 91: 4082-4085.
39. Kenyon B, Browne F, D'Amato R. Effects of thalidomide and related metabolites in mouse corneal model of neovascularization. Exp Eye Res 1997; 64: 971-978. (Pubitemid 27314772)
40. Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol 1998; 55: 1827-1834.
41. Bizouarne N, Denis V, Legrand A et al. A SV-40 immortalized murine endothelial cell line from peripheral lymph node high endothelium expresses a new alpha-L-fucose binding protein. Biol Cell 1993; 79: 209-218. (Pubitemid 24110556)